<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102011</url>
  </required_header>
  <id_info>
    <org_study_id>00-046</org_study_id>
    <secondary_id>MSKCC-00046A</secondary_id>
    <secondary_id>UMN-2003NT062</secondary_id>
    <nct_id>NCT00102011</nct_id>
  </id_info>
  <brief_title>Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer</brief_title>
  <acronym>00-046</acronym>
  <official_title>Colonoscopy Screening Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Screening tests, such as colonoscopy and fecal occult blood test, may help doctors&#xD;
      find tumor cells early and plan better treatment for colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying colonoscopy to see how well it works&#xD;
      compared to fecal occult blood test in screening healthy participants for colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the neoplastic outcome of participants at average risk for colorectal cancer who&#xD;
           undergo colonoscopy vs annual fecal occult blood tests.&#xD;
&#xD;
        -  Compare the endoscopic and clinical resources required for these screening methods in&#xD;
           these participants.&#xD;
&#xD;
        -  Compare the benefit-to-harm ratio in participants undergoing these screening methods.&#xD;
&#xD;
        -  Determine the level of participation of participants undergoing these screening methods.&#xD;
&#xD;
      OUTLINE: This is a randomized, two-part, multicenter study.&#xD;
&#xD;
      Participants are asked whether they are interested in participating in a randomized&#xD;
      controlled trial of colorectal cancer screening.&#xD;
&#xD;
        -  Screening colonoscopy feasibility study I (accrual completed as of 12/14/2004):&#xD;
           Participants who are interested in participating in a screening trial are randomized to&#xD;
           1 of 2 screening arms.&#xD;
&#xD;
             -  Arm I: Participants undergo baseline screening colonoscopy.&#xD;
&#xD;
             -  Arm II: Participants receive standard care.&#xD;
&#xD;
        -  Screening colonoscopy feasibility study II: Participants who are interested in&#xD;
           participating in a screening trial are randomized to 1 of 2 screening arms.&#xD;
&#xD;
             -  Arm I: Participants undergo baseline screening colonoscopy. Participants are given&#xD;
                individualized recommendations for further surveillance based on the results of the&#xD;
                colonoscopy.&#xD;
&#xD;
             -  Arm II: Participants undergo a baseline fecal occult blood test (FOBT).&#xD;
                Participants are given individualized recommendations for further surveillance&#xD;
                based on the results of the FOBT. Participants with negative baseline FOBT undergo&#xD;
                FOBT annually for up to 4 years in the absence of a positive FOBT.&#xD;
&#xD;
      All participants are followed annually for up to 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,402 participants (701 per screening arm) have been accrued&#xD;
      for feasibility study I within 3 years (accrual completed as of 12/14/2004). An additional&#xD;
      3,550 participants (1,775 per screening arm) will be accrued for feasibility study II within&#xD;
      5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neoplastic findings as assessed by screening colonoscopy vs annual fecal occult blood test (FOBT)-directed colonoscopy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Burden on endoscopic and clinical resources</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Harms associated with screening colonoscopy vs annual FOBT-directed colonoscopy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Benefit-to-harm ration for screening colonoscopy vs annual FOBT-directed colonoscopy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4952</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Study I- Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo baseline screening colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study I- Arm II</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study II- Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study II- Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>annual screening</intervention_name>
    <description>Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT</description>
    <arm_group_label>Study II- Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fecal occult blood test</intervention_name>
    <description>Participants undergo a baseline fecal occult blood test (FOBT)</description>
    <arm_group_label>Study I- Arm II</arm_group_label>
    <arm_group_label>Study II- Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>screening colonoscopy</intervention_name>
    <description>Patients undergo baseline screening colonoscopy</description>
    <arm_group_label>Study I- Arm I</arm_group_label>
    <arm_group_label>Study II- Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
    <description>Standard care</description>
    <arm_group_label>Study I- Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy participants at average risk for developing colorectal cancer&#xD;
&#xD;
          -  No history of colorectal cancer&#xD;
&#xD;
          -  No history of familial adenomatous polyposis&#xD;
&#xD;
          -  More than 5 years since prior flexible sigmoidoscopy&#xD;
&#xD;
          -  No prior colonoscopy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  50 to 69 (40 to 69 at the Louisiana State University participating site)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of ulcerative colitis&#xD;
&#xD;
          -  No history of Crohn's disease&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No serious comorbid condition&#xD;
&#xD;
          -  No consumption of red meat within 3 days prior to and during FOBT (feasibility study&#xD;
             II, arm II only)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy other than for nonmelanoma skin cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No vitamin C consumption &gt; 250 mg within 3 days prior to and during fecal occult blood&#xD;
             testing (FOBT) (feasibility study II arm II only)&#xD;
&#xD;
          -  No nonsteroidal anti-inflammatory drugs within 7 days prior to and during FOBT&#xD;
             (feasibility study II, arm II only)&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No concurrent anticancer therapy except for treatment of nonmelanoma skin cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Zauber, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota (Data collection only)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Washington Health Research Institute (Data collection only)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-1466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <reference>
    <citation>Shaukat A, Church TR, Shanley R, Kauff ND, O'Brien MJ, Mills GM, Jordan PA, Allen JA, Kim A, Feld AD, Zauber AG, Winawer SJ. Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy. Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):913-20. doi: 10.1158/1055-9965.EPI-14-1321. Epub 2015 Mar 23.</citation>
    <PMID>25800242</PMID>
  </reference>
  <reference>
    <citation>Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG. Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15.</citation>
    <PMID>28419856</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2005</study_first_submitted>
  <study_first_submitted_qc>January 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2005</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

